Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States f...

Full description

Bibliographic Details
Main Authors: Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Eric Jourdan, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Derek Tang, Pranav Abraham, Jennifer Lord-Bessen, Shelonitda Rose, Shien Guo, Weiqin Liao, Ruben A. Mesa
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000562

Internet

http://journals.lww.com/10.1097/HS9.0000000000000562

Similar Items